Narcolepsy Type 2

Neurology·MeSH: Narcolepsy

Prevalence

30.0 / 100K

5 drugs in development·3 companies·9 clinical trials

Drug Pipeline by Phase

Phase 3(3)

Drug	Company
ALKS 2680	Alkermes plc. (ALKS)
tak-360	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
tak-360	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)

Phase 2/Phase 3(2)

Drug	Company
Alixorexton (ALKS 2680)	Alkermes plc. (ALKS)
tak-360	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)

BioSniper tracks 5 drugs in development for Narcolepsy Type 2 across 3 companies.

There are 9 clinical trials targeting Narcolepsy Type 2 tracked by BioSniper.

The estimated prevalence of Narcolepsy Type 2 is approximately 30.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.